Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2003
10/22/2003EP1353689A2 Immunizing compositions and methods of use
10/22/2003EP1353688A2 Method and compositions for immunization with the pseudomonas v antigen
10/22/2003EP1353687A2 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof
10/22/2003EP1353675A2 New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
10/22/2003EP1353672A2 Synthesis of 3-amino-thalidomide and its enantiomers
10/22/2003EP1353569A2 Preparation for improved dietary utilisation
10/22/2003EP1192122B1 Benzene derivatives, preparation method and pharmaceutical compositions containing same
10/22/2003EP1104446B1 Biologically active fraction of vegetable melanin, process for its production and its use
10/22/2003EP1047665B1 Matrix metalloprotease inhibitors
10/22/2003EP0986572B1 Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
10/22/2003EP0948319B1 Encapsulated cells producing antibodies
10/22/2003EP0851927B1 Compounds for immunotherapy and diagnosis of tuberculosis
10/22/2003EP0764167B1 Bicycling lactam inhibitor of interleukin-1-beta converting enzyme
10/22/2003CN1451045A IFN-alpha homologues
10/22/2003CN1451043A Dual specificity antibodies and methods of making and using
10/22/2003CN1451015A Insect poison allergens with reduced LgE reactivity and method for producing the same
10/22/2003CN1451010A Benzosulfones with calcium antagonist activity
10/22/2003CN1451009A Glucocortiocoid-selective antinflammatory agents
10/22/2003CN1451004A 7-oxo pyridopyrimidines
10/22/2003CN1450999A Novel piperazine derivatives
10/22/2003CN1450998A Inhibitors of copper-containing amine oxidases
10/22/2003CN1450997A Inhibitors of copper-containing amine oxidases
10/22/2003CN1450912A CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions
10/22/2003CN1450891A Formulation based on heparin, glycosaminogl ycan or heparinoid, use of the formulation and the formulation base
10/22/2003CN1450075A Group No.1 oligose and sulfated products, their preparation process and medicine composition containing said oligose
10/22/2003CN1449825A Method for inactivating Bordetella bronchiseptica culture, bacteria composition prepared by same and vaccine having same and use thereof
10/22/2003CN1449792A Medicine composition with synergrstic action and preparation process and use thereof
10/22/2003CN1449760A Composition of danazol semisolid skeleton preparation
10/22/2003CN1125082C Human chemokine beta-8 chemokine beta-1 and macrophage inflammatory protein-4
10/22/2003CN1125079C Cyclopeptolides
10/22/2003CN1125070C Pyrrolo [2,3-d] pyrmidine compounds, and compositions and use thereof
10/22/2003CN1125054C Novel imidazolidine derivatives, their preparation their use and pharmaceutical preparations comprising them
10/22/2003CN1124843C Stable glassy state powder formulations
10/21/2003US6635786 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use
10/21/2003US6635762 Monocyclic-7H-pyrrolo[2,3-d]pyrimidine compounds, compositions, and methods of use
10/21/2003US6635749 Auxotrophic attenuated strain of Listeria with a mutation in genes whose protein product is essential for growth used to elicit a t-cell immune response to an antigen
10/21/2003US6635744 Substantially pure fibroblast growth factor homologous factor-4 polypeptide having specified amino acid sequence; diagnosis and treatment of neurodegenerative and neoplastic disorders
10/21/2003US6635680 Controlled release pellet formulation
10/21/2003US6635650 Such as N-(2-(7-(2-((8-(2-(acetyl-amino)ethyl)-2-naphthyl) oxy)ethoxy)-1-napthyl)ethyl)acetamide for treating or preventing melatoninergic disorders
10/21/2003US6635644 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli
10/21/2003US6635642 Poly(ADP-ribose) polymerase inhibitors; tissue damage treatment
10/21/2003US6635640 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
10/21/2003US6635633 Substituted pyrazoles useful for treating autoimmune diseases mediated by cathepsin S
10/21/2003US6635629 For therapy and prophylaxis of inflammation, asthma, an allergic disease, chronic obstructive pulmonary disease, atopic dermatitis, solid tumors, AIDS, ischemia, and cardiac arrhythmias
10/21/2003US6635622 Having anti-tumor activity and immunostimulating activity
10/21/2003US6635621 Alpha amino acid amide derivatives; reducing cathepsins B, L, S and/or K activity
10/21/2003US6635255 CASB414:antigen overexpressed in several tumors
10/21/2003US6635251 Eotaxin-specific antibodies
10/21/2003US6635250 Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsus
10/21/2003CA2310318C Pseudopolymorphic forms of 2-[2-[4-[bis (4-fluorophenyl) methyl]-1-piperazinyl] ethoxy]acetic acid dihydrochloride
10/21/2003CA2288003C Pharmaceutical compositions of tizoxanide and nitazoxanide
10/21/2003CA2257898C Use of aminothiolester derivatives in pharmaceutics
10/21/2003CA2182289C Immuno-stimulatory monoclonal antibodies
10/21/2003CA2157659C Use of porcine gal .alpha. (1,3) galactosyl transferase in xenograft therapies
10/16/2003WO2003085119A1 METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
10/16/2003WO2003085118A1 Process for producing antibody composition
10/16/2003WO2003085107A1 Cells with modified genome
10/16/2003WO2003085102A1 Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
10/16/2003WO2003085089A2 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
10/16/2003WO2003084979A2 Novel peptides and the application thereof in therapy
10/16/2003WO2003084966A1 Oxazolidinone derivatives
10/16/2003WO2003084961A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003WO2003084955A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity
10/16/2003WO2003084954A1 Tropane derivatives as ccr5 modulators
10/16/2003WO2003084952A1 Benzoxazinone-derived compounds, their preparation und use as medicaments
10/16/2003WO2003084951A1 (3z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
10/16/2003WO2003084950A1 Synthesis of piperidine and piperazine compounds as ccr5 antagonists
10/16/2003WO2003084943A2 Terphenyl derivatives, preparation thereof, compositions containing same
10/16/2003WO2003084941A2 Hydroxamic acid derivatives
10/16/2003WO2003084939A1 Benzoxazinone derivatives, the preparation and use thereof as medicaments
10/16/2003WO2003084938A2 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
10/16/2003WO2003084937A2 Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
10/16/2003WO2003084936A2 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
10/16/2003WO2003084935A2 Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
10/16/2003WO2003084917A1 (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
10/16/2003WO2003084570A1 DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
10/16/2003WO2003084569A1 Drug containing antibody composition
10/16/2003WO2003084562A1 Chemokines mutants having improved oral bioavailability
10/16/2003WO2003084560A2 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
10/16/2003WO2003084554A1 Willow extract
10/16/2003WO2003084553A1 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
10/16/2003WO2003084549A1 Hormone replacement therapy
10/16/2003WO2003084545A1 Drug containing riboflavin compound
10/16/2003WO2003084539A2 New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
10/16/2003WO2003084530A1 Novel therapeutical use of byakangelicin
10/16/2003WO2003084527A1 Severe sepsis preventive therapeutic agent
10/16/2003WO2003084524A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003WO2003084521A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003WO2003070701A3 Syntheses of quinazolinones
10/16/2003WO2003068954A3 Microorganism for genetic therapeutic treatment of proliferative diseases
10/16/2003WO2003062276A3 Multimers of receptor-binding ligands
10/16/2003WO2003061620A3 Peptide-carrying bodies for immune response
10/16/2003WO2003059282A3 Human monoclonal antibodies against cd30
10/16/2003WO2003057729A3 Mammal prolactin variants
10/16/2003WO2003051393A3 Enzymatic cleavable reagents for specific delivery to disease sites
10/16/2003WO2003048772A3 Detection d'autoanticorps reactifs aux molecules antigenes d'ilots pancreatiques et/ou a l'insuline Detection of autoantibodies reactive molecules to antigens of pancreatic islets and / or insulin
10/16/2003WO2003045414A3 Use of laminarin in the treatment of cancer as well as bacterial, viral and fungal infections
10/16/2003WO2003045335A3 Stem cell screening and transplantation therapy for hiv infection
10/16/2003WO2003039469A3 Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
10/16/2003WO2003039231A3 Compounds and methods for treating transplant rejection
1 ... 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 ... 1172